ImmunoPrecise Antibodies Ltd (TSXV:IPA) (OTC:IPATF) – Company Profile

ImmunoPrecise Antibodies Ltd (TSXV:IPA) (OTC:IPATF) – Company Profile
Quote Close Prices Trades Chart News Company Analyst Corp. Events Share Info Key Ratios Filings Earnings

ImmunoPrecise Antibodies Company Profile

Headquartered in Victoria, British Columbia, ImmunoPrecise Antibodies Ltd. (TSXV:IPA) (OTC:IPATF) is the preeminent supplier of custom antibodies to the global research industry and industrial community.

IPA offers a selection of high-quality antibody products to the research and industrial community and brings more than 25 years of experience in the custom antibodies business. The company is also increasing its panel of antibodies specific for out-licensing.

ImmunoPrecise has become the industry’s leading contract research organization (CRO) by providing advanced therapeutic immunization strategies in transgenic animals, complementary and innovative antibody discovery offerings, multiple B cell screening platforms, diverse species phage display, preclinical capabilities, and strategic investments.

IPA prides itself on its high customer satisfaction and takes a personalized approach to generate antibodies that meet the specific needs of its clients, which include academic researchers, scientists in the biotech and pharmaceutical sector, and government employees.

IPA’s founder Robert Beecroft has implemented three key methodologies that set ImmunoPrecise apart from other antibody companies. These methodologies are the Rapid Prime immunization strategy in mice; Single-Step cloning for HAT selection of hybridomas; and B-cell Selection recombinant monoclonal antibody technology for the generation of rabbit, rodent, and human monoclonal antibodies.

The company’s state-of-the-art laboratory is located at the Vancouver Island Technology Park and boasts a B cell facility and a Canadian Council for Animal Care (CCAC) animal care unit.

 

Becoming the Industry’s “Partner of Choice”

ImmunoPrecise is the industry’s only true single source antibody discovery contract research organization (CRO). IPA is focused on becoming the industry’s “partner of choice” for the therapeutic treatment of major diseases with its world-class scientific team, global footprint, and unrivaled platform suite.

The company’s full-service package allows it to assist clients from the moment they identify a therapeutic target to the time they are preparing to apply for an investigational review of the clinical product.

IPA is the world leader in transgenic animals and in display technologies, two principal technologies used for therapeutic antibody discovery. Combine this with the company’s custom immune and naive libraries and it’s easy to see why IPA is poised to become the world’s premier therapeutic antibody discovery CRO.

Meet the ImmunoPrecise Antibodies Team

ImmunoPrecise Antibodies

Jennifer Bath, Ph.D.

President and Chief Executive Officer

Dr. Jennifer Bath adds significant senior leadership and scientific depth to the ImmunoPrecise leadership team, along with broad experience in vaccine and therapeutic design, development, and testing. She holds a Ph.D. in Cellular and Molecular biology and a Bachelor’s degree in Biology, with an emphasis on human genetics. She served a 15-year appointment as Associate Professor of Cellular and Molecular Biology at Concordia College in Minnesota and founded the Concordia College Global Vaccine Institute. Prior to being appointed President and CEO of ImmunoPrecise, Jennifer Bath served in an executive role at Aldevron, LLC, as the Global Director of Client Relations.

 

 

ImmunoPrecise Antibodies

 

Lisa Helbling

Chief Financial Officer

Lisa Helbling brings over 30 years of broad experience in accounting, finance, enterprise risk management, audit, and ESOPs to the ImmunoPrecise leadership team. As Chief Financial Officer, Lisa oversees financial and strategic management, which includes the company’s financial reporting and long-range business planning and supervises human resources and legal. Prior to joining the ImmunoPrecise team, Lisa served as CFO at Anchor Ingredients and TMI Hospitality. She was also previously the VP of Internal Audit and Business Risk Management at Otter Tail Corporation.

 

 

ImmunoPrecise Antibodies

 

Chip Wheelock

Chief Technology Officer

Chip Wheelock brings a diverse background to his role as Chief Technology Officer at ImmunoPrecise. Over the past 25 years, Chip has held leadership positions in the software development and services industries encompassing global ERP deployments, cloud transformations, and building strategic lines of business applications. As CTO, Chip is responsible for overseeing all information technology aspects of IPA. He works closely with the executive management team and unit business leaders to grow the company through the use of software and technology services.

 

 

ImmunoPrecise Antibodies

Kari Graber

Director of Global Project Management

Kari Graber is the Director of Global Project Management for IPA and is responsible for the overall leadership and implementation of the Project Management program throughout ImmunoPrecise’s global family of companies. She holds a Bachelor of Science in Food Science & Technology with a Minor in Microbiology and brings over 20 years of experience in developing, implementing, and directing laboratory operations, regulatory compliance, quality assurance, and supply chain management programs to the role. She also spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Before joining the ImmunoPrecise team, Kari held a client relations management role at Aldevron LLC.

 

ImmunoPrecise Antibodies

 

Jason Orloske

VP of Operations

Jason Orloske brings a masters degree in Project management and has a diverse background of nearly 20 years of experience in project portfolio management and strategic delivery to his role as the Vice President of Operations for ImmunoPrecise. He is responsible for operationalizing strategic initiatives and helping drive growth. He works with executives and senior management teams to uncover challenges and opportunities being faced and develops a right-sized strategy that aligns with organizational vision.

 

Robert Beecroft

Founder and Director

Robert Beecroft brought over 25 years of experience in the development of innovative and proprietary methods for the production of monoclonal and polyclonal antibodies and peptides to the table when he founded ImmunoPrecise Antibodies in 1989. Prior to last year, Robert served as the company’s Chief Executive Officer and President. Robert has been involved in over 15 Research Projects and holds a B.Sc. in Microbiology from the University of Victoria. In 2015, Robert received the UVic Distinguished Alumni Award for the Faculty of Science, in recognition for founding ImmunoPrecise Antibodies Ltd.


Disclosure:

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on my research and understanding of the sector.

2) The Article was issued on behalf of a third party, ImmunoPrecise Antibodies Ltd. Market Jar Media Inc. has or expects to receive the following amounts from Native Ads Inc. in the amount of one hundred nine thousand nine hundred thirty seven American dollars and fifty cents for 21 campaign days (14 business days) for digital marketing. This featured profile page will be featured for a total of 180 days.

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on Market Jar Media Inc. should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on Market Jar Media Inc.

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.